Baxter International Inc. (BAX) Return on Equity (ROE): -18.17%
Is Baxter International Inc.’s return on equity (ROE) high or low?
Baxter International Inc.'s return on equity (ROE) of -18.17% is 1230% below its 5-year average of -1.37%, around the middle of its 5-year range (-41.71%–31.61%).
The return on equity (ROE) for Baxter International Inc. (BAX) is -18.17% as of Thursday, June 11, 2026. It is below its 12-month average by 45.77% (-12.46%).
BAX Return on Equity (ROE) Chart
BAX Average Return on Equity (ROE) Chart
BAX Current vs Average Return on Equity (ROE) Chart
BAX Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
-18.17%
RETURN ON EQUITY (ROE) AVG TTM
-12.46%
RETURN ON EQUITY (ROE) AVG 3Y
-8.76%
RETURN ON EQUITY (ROE) AVG 5Y
-1.37%
RETURN ON EQUITY (ROE) AVG 10Y
9.24%
RETURN ON EQUITY (ROE) AVG 15Y
15.32%
RETURN ON EQUITY (ROE) AVG 20Y
17.96%
CURRENT VS TTM AVG
-45.77%
CURRENT VS 3Y AVG
-107.48%
CURRENT VS 5Y AVG
-1229.51%
CURRENT VS 10Y AVG
-296.65%
CURRENT VS 15Y AVG
-218.62%
CURRENT VS 20Y AVG
-201.15%
BAX Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Baxter International Inc. (BAX) | $10.49B | -18.17% | -12.46% | -8.76% | -1.37% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | -6.28% | -2.13% | 6.32% | 9.65% |
| Align Technology, Inc. (ALGN) | $12.56B | 10.36% | 10.54% | 10.84% | 19.93% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 2.46% | -8.94% | -15.72% | 1.14% |
| Hims & Hers Health, Inc. (HIMS) | $6.42B | -2.97% | 25.09% | 5.57% | 0.40% |
| Hologic, Inc. (HOLX) | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| Moderna, Inc. (MRNA) | $18.40B | -43.12% | -32.64% | -13.90% | 0.25% |
| BioNTech SE (BNTX) | $21.81B | -6.79% | -4.55% | 10.63% | 21.70% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | -3677.41% | -2178.82% | -341.14% | -117.12% |
| Waters Corporation (WAT) | $23.83B | 2.94% | 29.98% | 64.02% | 111.55% |
Return Analysis
ROE
-18.2%
ROA
-5.5%
Baxter International Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Baxter International Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Baxter International Inc. (BAX)?
- The return on equity (ROE) for BAX stock is -18.17%.
- Is Baxter International Inc.'s return on equity (ROE) high or low?
- Baxter International Inc.'s return on equity (ROE) of -18.17% is 1230% below its 5-year average of -1.37%, around the middle of its 5-year range (-41.71%–31.61%).
- What is the TTM average return on equity (ROE) for Baxter International Inc. (BAX)?
- The TTM average return on equity (ROE) for BAX stock is -12.46%.
- What is the 3Y average return on equity (ROE) for Baxter International Inc. (BAX)?
- The 3Y average return on equity (ROE) for BAX stock is -8.76%.
- What is the 5Y average return on equity (ROE) for Baxter International Inc. (BAX)?
- The 5Y average return on equity (ROE) for BAX stock is -1.37%.
- What is the 10Y average return on equity (ROE) for Baxter International Inc. (BAX)?
- The 10Y average return on equity (ROE) for BAX stock is 9.24%.
- What is the 15Y average return on equity (ROE) for Baxter International Inc. (BAX)?
- The 15Y average return on equity (ROE) for BAX stock is 15.32%.
- What is the 20Y average return on equity (ROE) for Baxter International Inc. (BAX)?
- The 20Y average return on equity (ROE) for BAX stock is 17.96%.
Baxter International Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -15.61% |
| 2024-12-31 | -9.32% |
| 2023-12-31 | 31.61% |
| 2022-12-31 | -41.71% |
| 2021-12-31 | 14.15% |
| 2020-12-31 | 12.68% |
| 2019-12-31 | 12.70% |
| 2018-12-31 | 19.71% |
| 2017-12-31 | 6.60% |
| 2016-12-31 | 59.89% |
| 2015-12-31 | 10.94% |
| 2014-12-31 | 30.75% |
| 2013-12-31 | 23.77% |
| 2012-12-31 | 33.53% |
| 2011-12-31 | 33.77% |
| 2010-12-31 | 21.62% |
| 2009-12-31 | 30.66% |
| 2008-12-31 | 32.33% |
| 2007-12-31 | 24.68% |
| 2006-12-31 | 22.26% |
| 2005-12-31 | 22.24% |
| 2004-12-31 | 10.47% |
| 2003-12-31 | 26.45% |
| 2002-12-31 | 26.23% |
| 2001-12-31 | 16.29% |
| 2000-12-31 | 27.83% |
| 1999-12-31 | 23.81% |
| 1998-12-31 | 11.10% |
| 1997-12-31 | 11.45% |
| 1996-12-31 | 26.72% |
Related Metrics
About Baxter International Inc.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Andrew Hider